With proof of concept for its NAV platform from two gene therapy products partners have brought to the market, two products slated for regulatory submission in the next two years, and a new manufacturing facility, Regenxbio Inc. is poised to take the next step to becoming a fully realized commercial biotech, CEO Kenneth Mills told Scrip in a recent interview.
The progress is all part of the Rockville, MD-based biotech’s “5x25” strategy to bring five gene therapy candidates either to...








